CLINICAL TRIALS PROFILE FOR SKLB1028
✉ Email this page to a colleague
Clinical Trials for SKLB1028
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02859948 ↗ | A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Unknown status | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Patients will receive oral SKLB1028 for 28 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations. |
NCT04015024 ↗ | A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients | Unknown status | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Patients will receive oral SKLB1028 for 28 days as a course of treatment, and then to evaluate the side effects,tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations. |
NCT04716114 ↗ | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated | Recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 | This is a randomized,multicenter, open-label Phase III, clinical study to confirm the efficacy and safety of SKLB1028 in patients with relapsed or refractory(R/R) FLT3-Mutated Acute Myeloid Leukemia(AML)compared to salvage chemotherapy. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for SKLB1028
Condition Name
Clinical Trial Locations for SKLB1028
Clinical Trial Progress for SKLB1028
Clinical Trial Phase
Clinical Trial Sponsors for SKLB1028
Sponsor Name